Cracow

• Investigation of Radium-223 dichloride (Xofigo), a treatment that gives off radiation that helps kill cancer cells, compared to a treatment … Ended recruitment
  2023-505830-89-00 6 2020-08-05 metastatic castrate resistant prostate cancer (mCRPC)
• PACIFICA: A Phase 3 Study of Pacritinib in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thro … Ended recruitment
  2024-515953-52-00 5 2020-07-24 Post-Essential Thrombocythaemia Myelofibrosis
• A Phase 3 study to compare long-term efficacy and safety of macitentan 75 mg versus 10 mg in Pulmonary Arterial Hypertension. Ended recruitment
  2024-515669-32-00 5 2020-06-30 Pulmonary arterial hypertension
• A global trial to determine the effectiveness and safety of ION-682884 in patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR- … Ended recruitment
  2024-514434-20-00 5 2020-06-29 Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
• A study of belantamab mafodotin compared to a combination of pomalidomide and dexamethasone in participants with relapsed/refractory multipl … Ended recruitment
  2023-508962-14-00 5 2020-06-18 Relapsed/Refractory Multiple Myeloma
• Extension of a clinical trial to assess the safety of a study drug called "CORT125134" in the treatment of Cushing Syndrome Ended recruitment
  2024-514079-17-00 10 2020-05-28 Endogenous Cushing Syndrome
• An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis Ended recruitment
  2024-516680-91-00 5 2020-05-21 relapsing multiple sclerosis
• Phase III study of GSK2857916, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in participants with relapsed … Ended recruitment
  2023-510537-28-00 5 2020-05-15 Multiple Myeloma
• Phase III Study of Capivasertib + Fulvestrant vs Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2 … Ended recruitment
  2023-505042-25-00 5 2020-05-05 Locally advanced (inoperable) or metastatic HR+/HER2 breast cancer
• Phase III study of Pembrolizumab plus chemoradiation vs chemoradiation along for patients with muscle invasive bladder cancer Ended recruitment
  2023-503500-87-00 11 2020-03-17 Muscle Invasive Bladder Cancer
• A multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients wit … Ended recruitment
  2023-508292-37-00 5 2020-03-06 Cardiovascular Disease
• A clinical study to investigate the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral trea … Ended recruitment
  2024-511940-20-00 5 2020-02-05 Parkinson's disease
• Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell … Ended recruitment
  2023-509908-15-00 10 2020-01-20 Mantle Cell Lymphoma
• The TARGET BP I Ended recruitment
  2024-512525-83-00 5 2020-01-07 Hypertension
• A Study of the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis Ended recruitment
  2023-504718-31-00 10 2019-10-19 Moderately to Severely Active Ulcerative Colitis
• Study to compare the efficacy and safety of NT 201 (botulinum toxin) with placebo for the treatment of lower limb spasticity caused by strok … Ended recruitment
  2023-505810-12-00 5 2019-09-03 Lower limb spasticity
• A study of androgen deprivation therapy (ADT) plus apalutamide in patients with prostate cancer Ended recruitment
  2023-506153-38-00 5 2019-07-11 High-risk localized or locally advanced prostate cancer
• A Phase IB/II Study to determine efficacy and safety of Durvalumab + Paclitaxel and Durvalumab in Combination with Novel Oncology Therapies … Ended recruitment
  2024-511646-40-00 9 2019-07-11 First-line (1L) Stage IV Triple Negative Breast Cancer (TNBC) - the su
• A Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Respo … Ended recruitment
  2023-505477-33-00 5 2019-06-18 Psoriatic Arthritis
• A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant trea … Ended recruitment
  2023-510357-42-00 5 2019-05-22 hormone receptor (HR)-positive, HER2-negative, early breast cancer (EB
• A Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or … Ended recruitment
  2023-505478-14-00 5 2019-05-09 Psoriatic Arthritis
• A research study to look at how semaglutide compared to placebo affects diabetic eye disease in people with type 2 diabetes (FOCUS) Ended recruitment
  2023-506827-26-00 5 2019-05-02 While it is well-established that long-term good glycaemic control wil
• This study is being done to test the effectiveness and safety of an investigational drug called acalabrutinib (ACP-196) when taken with alre … Ended recruitment
  2023-509349-11-00 5 2019-03-22 Previously untreated Chronic Lymphocytic Leukemia Without del(17p) or
• A global study of midostaurin in combination with chemotherapy to evaluate safety, efficacy, and pharmacokinetics in newly diagnosed pediatr … Ended recruitment
  2023-509834-20-00 4 2019-03-13 untreated FLT3-mutated Acute Myeloid Leukemia

Showing 721–744 of 1,081 trials